Publication Name	World Journal of Cardiology
Manuscript ID	8305
Country	Switzerland

Received	2013-12-25 09:00
Peer-Review Started	2013-12-25 14:48
First Decision by Editorial Office Director
Return for Revision	2014-01-20 17:32
Revised
Publication Fee Transferred
Second Decision by Editor	2014-03-18 15:02
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-03-18 15:26
Articles in Press
Edit the Manuscript by Language Editor	2014-03-27 00:54
Typeset the Manuscript	2014-05-28 09:34
Publish the Manuscript Online	2014-06-20 19:33

ISSN	1949-8462 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Review
Article Title	Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity
Manuscript Source	Invited Manuscript
All Author List	Nicolas Vuilleumier, Fabrizio Montecucco and Oliver Hartley
Funding Agency and Grant Number	Funding Agency Grant Number Swiss National Science Foundation 310030_140736 (to Dr. Vuilleumier N) Swiss National Science Foundation 32003B_134963/1 (to Dr. Montecucco F) Foundation “Gustave and Simone Prévot” to Dr. Montecucco F
Corresponding Author	Dr. Nicolas Vuilleumier, MD, PD, Head of Laboratory Medicine Division, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. nicolas.vuilleumier@hcuge.ch
Key Words	Autoantibodies; Cardiovascular disease; Atherosclerosis; Apolipoprotein A-1; Autoimmunity; Biomarkers
Core Tip	This review provides a comprehensive and critical analysis of the most recent basic research articles and clinical trials on the role of autoantibodies to apolipoprotein A-1 as biomarkers and potential mediators of cardiovascular diseases (CVD). Evidence from both in vitro and in vivo studies showed that anti-apolipoprotein A-1 IgG might have critical pro-atherosclerotic activities by activating immune cells to release pro-inflammatory mediators and proteases. In addition, these autoantibodies might increase heart rate and arrhythmias both in humans and animal models. These studies suggest a causal role of anti-apolipoprotein A-1 immunoglobulins of G class in CVD, indicating that those autoantibodies could potentially represent an emerging therapeutic target to better fight CVD.
Publish Date	2014-06-20 19:33
Citation	Vuilleumier N, Montecucco F, Hartley O. Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol 2014; 6(5): 314-326
URL	http://www.wjgnet.com/1949-8462/full/v6/i5/314.htm
DOI	http://dx.doi.org/10.4330/wjc.v6.i5.314

Full Article (PDF)	WJC-6-314.pdf
Full Article (Word)	WJC-6-314.doc
Manuscript File	8305-Review.doc
Answering Reviewers	8305-Answering reviewers.pdf
Copyright License Agreement	8305-Copyright assignment.pdf
Peer-review Report	8305-Peer reviews.pdf
Scientific Editor Work List	8305-Scientific editor work list.doc